Healthcare Equipment and Supplies
Company Overview of Zyomyx, Inc.
Zyomyx, Inc. engages in the development and commercialization of diagnostic platforms. The company offers disposable CD4 T-cell, a point-of-care test for HIV/AIDS treatment. Zyomyx, Inc. also provides a platform technology for cell counting. The company was founded in 1998 and is based in Fremont, California.
6519 Dumbarton Circle
Fremont, CA 94555
Founded in 1998
Key Executives for Zyomyx, Inc.
Co-Founder, Chief Executive Officer, President and Director
Director of Finance and Administration
Compensation as of Fiscal Year 2014.
Zyomyx, Inc. Key Developments
Zyomyx, Inc. Receives $7.5 Million from UNITAID to Commercialize its Quantitative MyT4 Point-of-Care CD4 Test
Mar 26 14
Zyomyx, Inc. has been awarded $7.5 million from UNITAID to commercialize its quantitative MyT4(TM) point-of-care CD4 test, designed to guide HIV/AIDS treatment initiation and monitoring in low- and middle-income countries. UNITAID's funding contribution is part of its strategy to speed up access to a range of new and improved technologies from a number of manufacturers for HIV/AIDS, tuberculosis and malaria for the world's most vulnerable populations. It will support field evaluations of the product, training for national HIV programs, and country-level and global regulatory filings. The Zyomyx test is the fastest point-of-care CD4 diagnostic on the market and delivers results that are equivalent to lab-based flow cytometry, the gold standard of CD4 testing. The MyT4(TM) CD4 test is commercially available receiving a CE Mark in December 2013.
Mylan, Inc. and Zyomyx, Inc. Enter into Exclusive Distribution Agreement for Innovative Point-of-Care CD4 Diagnostic Test
Jun 30 13
Mylan, Inc. announced that it has entered into an exclusive agreement with Zyomyx, Inc. for the rights to distribute Zyomyx's proprietary point-of-care (POC) CD4 T-cell count test in the developing world. CD4 count testing is a critical diagnostic component in treating HIV/AIDS, as medical professionals refer to a patient's CD4 count to determine when to begin and/or alter HIV treatment. As part of the agreement, Mylan also has made a strategic equity investment in Zyomyx. The Zyomyx POC CD4 test is currently in final stages of development and expected to launch in the near-term, pending applicable regulatory approvals. Mylan expects to distribute the portable, easy-to-use, low-cost test in the developing world alongside its broad portfolio of high quality, affordable generic antiretroviral (ARV) drugs in order to improve access to and guide HIV/AIDS treatment in resource-limited settings. To complement the exclusive agreement with Zyomyx, Mylan also announced that it has signed a Global Access Commitment with the Bill & Melinda Gates Foundation, an investor in Zyomyx. Mylan has committed to ensuring that the Zyomyx POC CD4 technology can be made available and accessible at a reasonable price in high burden HIV countries. Increasing access to affordable and effective health interventions for those in need is a priority for the foundation.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries